{
  "docId": "019de072-1a15-7369-8097-68fb5b1d5017",
  "docSlug": "de0c004f3134112f269aa7aa17f1a1f3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 39,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a combination of patient population visualization (icons) and a mechanism-of-action (MOA) mapping against disease severity (NYHA scale).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-1a15-7369-8097-68fb5b1d5017/29",
  "deckHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017",
  "deckJsonHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017.json",
  "deckAnchorHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.52,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Building a strategic presence in amyloidosis",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c5fdd15-fd5a-4bfe-85a9-c7ce4c3821fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.52,
        "y": 0.275
      },
      "kind": "chart",
      "text": "Complementary MOAs needed in ATTR to address full spectrum of patient need",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f48c3265-0654-43d2-b227-023e26124818",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.42,
        "x": 0.04,
        "y": 0.38
      },
      "kind": "diagram",
      "text": "Farxiga in Heart Failure (HFrEF, HFpEF) followed by Amyloidosis commonly misdiagnosed as HFpEF",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23c0978d-a94c-40a8-900a-8f553f3b48a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.08,
        "y": 0.275
      },
      "kind": "paragraph",
      "text": "Leveraging strengths and expertise across Cardiovascular, Rare Disease",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99cf5cf2-13b6-444f-b201-60e609491d13",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Mohamed-Salem L et al. Int J Cardiol. 2018 Nov 1; 270:192-196. 2. Cucaden C, et al. J Nucl Cardiol. 2020 May 8 3. Quock, T. P., et al. Blood Adv.2018; 2(10):1046-1053; Internal epidemiological analysis: Mayo Stage IIIa + b 4. New York Heart Association (NYHA) Functional Classification. MoA = mechanism of acton.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11ccb921-8d46-4fd0-9b08-767ab899d044",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Cohesive commercial and development strategy across Cardiovascular and Rare Disease",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e18ace7-7c11-4dcc-a78e-40727062abe0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Expanding beyond heart failure in amyloidosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41fa7bf2-f110-4bde-908e-3217fb6e6b02",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "1e48f709-1f59-4344-83f3-5d8cb0e81713",
      "evidence": "diagram/process: Farxiga in Heart Failure (HFrEF, HFpEF) followed by Amyloidosis commonly misdiagnosed as HFpEF",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "mechanism-of-action-mapping",
      "slug": null,
      "matchId": "47a050fd-f487-494b-8a05-1f4db5528856",
      "evidence": "Mapping of drug classes (Stabiliser, Silencer, Depleter) against NYHA severity scale",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 31,
      "from": 26,
      "beatId": "aad1cb9b-557b-4e95-ba5a-dc0050f283ae",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The closing remarks and Q&A session prompt action from the audience.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 26,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f69dbb94-83a9-490b-bc96-5831ed386c14",
      "evidence": "The presentation implies that not investing in the pipeline would mean missing out on growth opportunities.",
      "position": 1,
      "objective": "What are the consequences of not investing in AstraZeneca's pipeline?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}